SG

Mondelēz International Reports Q3 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Outlook, SG, Growth, Transport, Adjusted gross income, EPS, GAAP, Free cash flow, Acquisition, International, Tax, Webcast, Bank, Adjustment

CHICAGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today reported its third quarter 2023 results.

Key Points: 
  • Mondelēz International provides its outlook on a non-GAAP basis, as the company cannot predict some elements that are included in reported GAAP results, including the impact of foreign exchange.
  • For 2023, the company is updating its 2023 fiscal outlook and now expects 14 to 15 percent Organic Net Revenue growth versus the prior outlook of 12+ percent, which reflects the strength of its year-to-date performance.
  • The company estimates currency translation would decrease 2023 net revenue growth by approximately 4 percent3 with a negative $0.15 impact to Adjusted EPS3.
  • Mondelēz International will host a conference call for investors with accompanying slides to review its results at 5 p.m.

Climb Global Solutions Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Summary, SG, EBITDA, FX, GAAP, Acquisition, Growth, Natural borrowing limit, Investment, ERP, Elevate, Mobile phone, Video game, Pharmaceutical industry, Bank

EATONTOWN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb”, the “Company”, “we”, or “our”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, is reporting results for the third quarter ended September 30, 2023.

Key Points: 
  • EATONTOWN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb”, the “Company”, “we”, or “our”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, is reporting results for the third quarter ended September 30, 2023.
  • Net sales in the third quarter of 2023 increased 3% to $78.5 million compared to $76.3 million for the same period in 2022.
  • Gross profit in the third quarter of 2023 increased 6% to $14.3 million compared to $13.5 million for the same period in 2022.
  • The Company will conduct a conference call tomorrow, November 2, 2023, at 8:30 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2023.

UFP Technologies Announces Strong Q3 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Adjustment, Sale, UFP Technologies, Dominican Republic, Bailly, SG, Medicine, EBITDA, News, GAAP, Acquisition, UFP, Growth, Dominican, Hyperaccumulators table – 3, Investment, COVID-19, Video game, Q3

Adjusted net income increased 44.4% to $35.8 million for the nine-month period ended September 30, 2023 from $24.8 million in the same period of 2022.

Key Points: 
  • Adjusted net income increased 44.4% to $35.8 million for the nine-month period ended September 30, 2023 from $24.8 million in the same period of 2022.
  • Sales for the nine-month period ended September 30, 2023 were $298.6 million compared to sales of $262.6 million in the same period in 2022.
  • “I am pleased with our Q3 results and progress on our growth initiatives, particularly our expansion plans in our low-cost country facilities,” said R. Jeffrey Bailly, Chairman & CEO.
  • Adjusted EBITDA increased to $60.2 million for the nine-month period ended September 30, 2023 from $44.9 million in the same period of 2022.

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Research, European Commission, Medicare, II, SG, Treatment, Multiple sclerosis, Conference, EC, R, D, Centers for Medicare & Medicaid Services, Prescription, Clinical trial, TG, RMS, Finance, Conference call, Therapy, Patient, CMS, Pharmaceutical industry, Health insurance, Cryptocurrency

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2023, along with recent company developments.

Key Points: 
  • Achieved $25.1 million in BRIUMVI net sales for the third quarter 2023; total net product revenue of approximately $48.9 million since launch.
  • Received a permanent J-Code (J2329) for BRIUMVI from the U.S. Centers for Medicare & Medicaid Services (CMS), which became effective July 1, 2023.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $229.2 million as of September 30, 2023.
  • The Company will host a conference call today, November 1, 2023, at 8:30 AM ET, to discuss the Company’s financial results from the third quarter, ended September 30, 2023.

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 1, 2023
Survival, Patient, Research, SCLC, Patent, Event, Food, PIN, Pivotal, Thrombocytopenia, Public expenditure, SG, RESEARCH, Telephone, Organization, GAAP, Wind, Total revenue, Acquisition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, TNBC, Update, Clinical trial, Security, Webcast, Interim, Avelumab, Guideline, Anemia, G1 Therapeutics, Net, Therapy, Hospital, PARK, OS, Regenerative Medicine Advanced Therapy, Neutropenia, ASCO, Acceleration, Shanda, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency, Simcere Pharmaceutical, G1

Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.

Key Points: 
  • Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.
  • Vial volume grew 3% over the second quarter of 2023 despite the impact of an ongoing platinum-based chemotherapy shortage.
  • Ended the Third Quarter of 2023 with Cash, Cash Equivalents, and Marketable Securities of $94.4 Million.
  • Operating expenses for the third quarter of 2023 were $28.7 million, compared to $45.1 million for the third quarter of 2022.

Meritage Homes reports third quarter 2023 results with a 50% year-over-year increase in sales orders driven by accelerated cycle times and move-in ready inventory

Retrieved on: 
Tuesday, October 31, 2023
Internal Revenue Code, SG, Environment, IRA, Sale, ASP, Meritage Homes Corporation, Absorption, EPS, Inflation, Acquisition, Note, Video game, Bank, Lease, Life insurance, Cryptocurrency, SG&A

"Buoyed by our financing incentives including rate locks and buy-downs, our sales orders of 3,474 homes this quarter increased 50% year-over-year,” Mr. Lord continued.

Key Points: 
  • "Buoyed by our financing incentives including rate locks and buy-downs, our sales orders of 3,474 homes this quarter increased 50% year-over-year,” Mr. Lord continued.
  • "Third quarter 2023 average community count of 282 was 3% below prior year and down 1% sequentially compared to the second quarter of 2023, as our accelerated orders pace resulted in some early community close outs.
  • Average sales price ("ASP") on orders in the third quarter of 2023 of $430,000 was up 2% from the third quarter of 2022 due to geographic mix.
  • The lower rate for 2023 reflected the increased per-home energy efficiency credit amount starting in 2023.

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Retrieved on: 
Tuesday, October 31, 2023
Sale, Tax, SG, EBITDA, GAAP, Acquisition, Bank statement, Repligen, COVID, Stock, COVID-19, Income tax, Webcast, Depreciation, 2020–2022 Chinese property sector crisis, Table, Commercial property, Bank

As previously disclosed, in July 2023 we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations.

Key Points: 
  • As previously disclosed, in July 2023 we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations.
  • ET, to discuss third quarter 2023 financial results, corporate developments and financial guidance for the year 2023.
  • A reconciliation of GAAP to adjusted (non-GAAP) financial measures is included as an attachment to this press release.
  • When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

The Vita Coco Company Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, October 31, 2023
Health, Tax, Use, SG, EBITDA, Share repurchase, Carlisle Companies, Non, GAAP, Entrepreneurship, COCO, Growth, Transport, Marketing, Webcast, Depreciation, Investment, Movement, Pharmaceutical industry, Health care, Cryptocurrency, Bank, Adjustment

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the "Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Third Quarter Net Sales Increased 11% to $138MM; Year-To-Date Net Sales Grew 15%
    NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the "Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2023.
  • Net sales increased $14 million, or 11%, to $138 million for the third quarter ended September 30, 2023, compared to $124 million for the third quarter ended September 30, 2022.
  • SG&A expenses in the third quarter of 2023 were $33 million, compared to $24 million in the prior-year period.
  • The Vita Coco Company will host a conference call and webcast at 8:30 a.m.

Kforce Reports Third Quarter 2023 Revenue Of $373.1 Million; And Earnings Per Share Of $0.54, As Reported; As Adjusted For Certain Third Quarter Charges, Earnings Per Share Of $0.90

Retrieved on: 
Monday, October 30, 2023
Adjustment, KFRC, SG, GAAP, News, Kayvo Kforce, Growth, Webcast, Flex, Investment, Bias, Video game, Music

Revenue for the quarter ended September 30, 2023 was $373.1 million compared to $437.6 million for the quarter ended September 30, 2022, a decrease of 4.1% sequentially and 14.7% year-over-year.

Key Points: 
  • Revenue for the quarter ended September 30, 2023 was $373.1 million compared to $437.6 million for the quarter ended September 30, 2022, a decrease of 4.1% sequentially and 14.7% year-over-year.
  • As reported, SG&A expenses as a percentage of revenue was 23.1% for the quarter ended September 30, 2023, which increased 160 basis points year-over-year.
  • As reported, diluted earnings per share for the quarter ended September 30, 2023 were $0.54 per share, a decrease of 50% year-over-year.
  • Current estimates for the fourth quarter of 2023 are:
    On Monday, October 30, 2023, Kforce will host a conference call at 5:00 p.m. E.T.

Medifast Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Health, Fitness & Nutrition, Health Technology, Managed Care, NYSE, Tax, Fuel, SG, Pressure, Telephone, Acquisition, Research, Internet, EPS, Chard, Future, Pharmaceutical industry, Music, Medifast

Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA® , today reported results for the third quarter ended September 30, 2023.

Key Points: 
  • Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA® , today reported results for the third quarter ended September 30, 2023.
  • The total number of active earning OPTAVIA Coaches decreased 28.9% to 47,100 compared to 66,200 for the third quarter of 2022.
  • The company’s gross profit as a percentage of revenue was 75.2% compared to 72.5% in the third quarter of 2022.
  • The effective tax rate was 12.9% for the third quarter of 2023 compared to 24.5% in the prior-year period.